World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997
复制标题
DOI：
10.1200/jco.1999.17.12.3835
复制
发表时间：
1999-12-01
影响因子：
45.3
通讯作者：
Bloomfield, CD
中科院分区：
文献类型：
--
作者：
Harris, NL;Jaffe, ES;Bloomfield, CD
目的：欧洲血液病理学家协会和血液病理学会制定了一个新的世界卫生组织（WHO）血液恶性肿瘤分类，包括淋巴样、骨髓样、组织细胞和肥大细胞肿瘤，设计：十个病理学家委员会制定了疾病实体的列表和定义。一个临床咨询委员会（CAC）的国际血液学家和肿瘤学家形成，以确保分类将是有用的临床医生，CAC于1997年11月举行会议，讨论有关classification.Results的临床问题：世界卫生组织使用修订后的欧洲-美国淋巴瘤（真实的）分类，1994年出版的国际淋巴瘤研究组，分类淋巴肿瘤。REAL分类基于这样的原则，即分类是“真实的”疾病实体的列表，其通过形态学、免疫表型、遗传特征和临床特征的组合来定义。这些特征中的每一个的相对重要性在疾病之间变化，并且没有一个金标准，WHO分类将真实的分类的原则应用于骨髓和组织细胞肿瘤。髓系肿瘤的分类识别由形态学和细胞遗传学异常的组合定义的不同实体。在围绕一系列临床问题组织的CAC会议上，与会者就提出的大多数问题达成了共识。他们得出结论，淋巴肿瘤的临床分组既不必要也不可取。患者的治疗取决于淋巴瘤的具体类型，并在肿瘤类型内增加等级（如果适用）和临床预后因素，如国际预后指数。世界卫生组织的分类使世界各地的肿瘤学家和病理学家之间的合作和交流达到了一个新的令人兴奋的程度，其将促进血液恶性肿瘤的理解和治疗的进展，J Clin Oncol 17：3835-3849，（C）1999，美国临床肿瘤学会。
Purpose: The European Association of Hematopathologists and the Society for Hematopathology have developed a new World Health Organization (WHO) classification of hematologic malignancies, including lymphoid, myeloid, histiocytic, and mast cell neoplasms,Design: Ten committees of pathologists developed lists and definitions of disease entities. A clinical advisory committee (CAC) of international hematologists and oncologists was formed to ensure that the classification would be useful to clinicians, The CAC met in November 1997 to discuss clinical issues related to the classification.Results: The WHO uses the Revised European-American Lymphoma (REAL) classification, published in 1994 by the International Lymphoma Study Group, to categorize lymphoid neoplasms. The REAL classification is based on the principle that a classification is a list of "real" disease entities, which are defined by a combination of morphology, immunophenotype, genetic features, and clinical features. The relative importance of each of these features varies among diseases, and there is no one gold standard, The WHO classification applies the principles of the REAL classification to myeloid and histiocytic neoplasms. The classification of myeloid neoplasms recognizes distinct entities defined by a combination of morphology and cytogenetic abnormalities. At the CAC meeting, which was organized around a series of clinical questions, participants reached a consensus on most of the questions posed. They concluded that clinical groupings of lymphoid neoplasms were neither necessary nor desirable. Patient treatment is determined by the specific type of lymphoma, with the addition of grade within the tumor type, if applicable, and clinical prognostic factors, such as the International Prognostic Index.Conclusion: The WHO classification has produced a new and exciting degree of cooperation and communication between oncologists and pathologists from around the world, which should facilitate progress in the understanding and treatment of hematologic malignancies, J Clin Oncol 17:3835-3849, (C) 1999 by American Society of Clinical Oncology.